文献速递浆细胞疾病

极高危原发性免疫球蛋白轻链型淀粉样变患者的临床特征与转归分析

[Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

回顾性分析北京协和医院2009年1月至2016年2月205例原发性轻链型淀粉样变(pAL)患者,34例(16.6%)为极高危(梅奥2004分期Ⅲb期或梅奥2012分期4期)。极高危患者均有心脏受累,中位生存仅4个月,41.2%在诊断后3个月内死亡;获血液学缓解者1年预计存活率90.9%,未缓解者11.1%,姑息治疗者0(P<0.001)。

要点

  • 极高危pAL占16.6%,均有心脏受累,81.8%心功能3~4级。
  • 极高危pAL中位生存仅4个月,41.2%诊断后3个月内死亡。
  • 获血液学缓解者1年预计存活率90.9%,未缓解者11.1%,姑息治疗者0(P<0.001)。

核心结论

  • 极高危pAL患者预后极差,早期病死率高,获得血液学缓解的患者预后明显更好。

研究设计与样本

  • 回顾性分析2009年1月至2016年2月北京协和医院确诊的205例pAL患者的临床资料、治疗与转归。
  • 极高危组定义为梅奥2004分期Ⅲb期或梅奥2012分期4期的患者。

主要发现

  • 205例中34例(16.6%)为极高危pAL,中位年龄57(20~84)岁,男性22例(64.7%)。
  • 34例均诊断心脏受累,15例(44.1%)受累脏器≥3个,27例(81.8%)纽约心脏协会心功能分级Ⅲ或Ⅳ级。
  • 中位血清肌钙蛋白I 0.25(0.08~1.23)μg/L,中位N末端B型利钠肽前体11 733(1 892~103 277)ng/L,中位血清游离轻链差值403.0(18.1~1 911.6)mg/L,8例(24.2%)骨髓浆细胞比例≥0.100。
  • 16例(47.1%)采用硼替佐米为主的化疗方案,总体血液学缓解率58.3%。
  • 中位随诊27(1~40)个月,14例(41.2%)诊断后3个月内死亡,中位生存时间4个月,3、6、12和24个月预期生存率分别为51.3%、44.0%、35.2%和29.6%。

关键数值与推荐

  • 获得血液学缓解、未获得血液学缓解及姑息治疗患者1年预计存活率分别为90.9%、11.1%及0(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical characteristics and outcomes of very high risk patients with primary immunoglobulin light-chain amyloidosis (pAL) at a single center in China. Method: Clinical data, treatment and outcome of 205 pAL patients in Peking Union Medical College Hospital from January 2009 to February 2016 were retrospectively analyzed. A 'very high risk' group includes patients with Mayo 2004 stage Ⅲb and Mayo 2012 stage 4. Results: Of 205 patients, 34 (16.6%) were defined as very high risk pAL patients. The median age at diagnosis was 57 (20-84) years, and 22 patients (64.7%) were male. All 34 patients were diagnosed with cardiac involvement, multi-organ involvement was observed in 15 patients (44.1%) , and 27 (81.8%) had New York Heart Association Class Ⅲ or Ⅳ. Median values of serum cTnI, NT-proBNP, and free light chains difference were 0.25 μg/L, 11 733 ng/L, and 403 mg/L, respectively. Eight (24.2%) had more than 10% plasma cell on the bone marrow aspirate. Sixteen (47.1%) patients received bortezomib based chemotherapy and overall hematologic response rate was 58.3%. Median overall survival (OS) was 4 months. The estimated OS at 3, 6, 12, and 24 months was 51.3%, 44.0%, 35.2%, and 29.6%, respectively. Fourteen (41.2%) patients died within 3 months after the diagnosis. The estimated 1-year survival rate for the patients who got hematologic response, without hematologic response, and palliative treatment was 90.9%, 11.1%, and 0, respectively (P<0.001) . Conclusion: Patients with very high risk pAL had very poor prognosis and the early death rate remained high. Those patients who obtained hematologic remission would have significantly better outcomes. 目的:探讨极高危原发性轻链型淀粉样变(pAL)患者的临床特征及其预后。 方法:回顾性分析2009年1月至2016年2月在北京协和医院确诊的205例pAL患者的临床资料,将梅奥2004分期Ⅲb期或梅奥2012分期4期的患者定义为极高危患者。 结果: 34例(16.6%)为极高危pAL患者,中位年龄57(20~84)岁,男性22例(64.7%)。所有患者均有心脏受累,15例(44.1%)患者的受累脏器≥ 3个。27例(81.8%)患者的心功能分级为3~4级,中位血清肌钙蛋白I为0.25(0.08~1.23)μg/L,中位血清N末端B型利钠肽前体为11 733(1 892~103 277)ng/L,中位血清游离轻链差值为403.0(18.1~ 1 911.6)mg/L,8例(24.2%)患者的骨髓浆细胞比例≥0.100。16例(47.1%)患者采用硼替佐米为主的化疗方案,总体血液学缓解率为58.3%。中位随诊27(1~40)个月,14例(41.2%)患者在诊断后3个月内死亡,中位生存时间仅为4个月。3、6、12和24个月的预期生存率分别为51.3%、44.0%、35.2%和29.6%。一线化疗后获得血液学缓解、未获得血液学缓解以及姑息治疗的患者1年预计存活率分别为90.9%、11.1%及0(P<0.001)。 结论:极高危pAL患者的预后极差,早期病死率高,获得血液学缓解的pAL患者有着明显更好的预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Feng J, Huang XF, Zhang CL, et al. [Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28279033. doi:10.3760/cma.j.issn.0253-2727.2017.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。